Malaria The Main Focus Of New GHIT Fund Allocations
This article was originally published in PharmAsia News
Japan's GHIT Fund is making new investments in a slew of pipeline projects for malaria, tuberculosis, leishmaniasis and dengue that involve local pharma industry and other academic partners.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.